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Abstract. Our gut harbours around 1014 bacteria of more than 1000 species, accounting for approximately 2 kg of 
biomass. The gut microbiome plays several vital functions in processes such as the development of the immune system, 
food digestion and protection against pathogens. For these functions to be beneficial for both host and microbiome, 
interactions are tightly regulated. Gut and immune cells continuously interact to distinguish among commensal 
microbiota, harmless foodstuff, and pathogens. A fine balance between inflammatory and anti-inflammatory state is 
fundamental to protect intestinal homeostasis. Nonsteroidal anti-inflammatories (NSAIDs) are a class of drugs used for 
management of pain and inflammation. These compounds have heterologous structures but similar therapeutic activities. 
The target of all NSAIDs are the isoforms of cyclooxygenase enzymes (COX): the primarily constitutive form COX-1, and 
the inducible from COX-2. Both isoforms catalyse the conversion of arachidonic acid to PGH2, the immediate substrate 
for specific prostaglandin and thromboxane synthesis. The gut microbiota plays a role in drug metabolism,  resulting in 
altered bioavailability of these compounds. Additionally, complex host-microbiome interactions lead to modified 
xenobiotic metabolism and altered expression of genes involved in drug metabolism. These effects can be at gut tissue-
level, or distant, including in the liver. Besides the gut microbiome influencing drug metabolism, drugs also impact the 
microbial communities in the gut. As different drugs exert selective pressures on the gut microbiome,  understanding this 
bidirectional relationship is crucial for developing effective therapies for managing chronic inflammation. 




The gut microbiota includes more than 100 trillion bac-
terial cells [1], which can be divided into six dominant 
phyla: Firmicutes, Bacteroidetes and Actinobacteria, 
and the less abundant Proteobacteria, Fusobacteria and 
Verrucomicrobia [2]. The human microbiome is not 
only composed of collective genomes from bacteria, but 
also from those of archaea, viruses, and eukaryotes col-
onizing the gut [3]. The composition of the microbiota 
will depend on environmental factors, diet, age and host 
genetics [4]. Inter- and intra-individual differences are 
significantly prevalent, although several species such as 
Faecalibacterium prausnitzii, Roseburia intestinalis and 
Bacteriodes uniformis have been consistently identified 
in large scale screenings. The gut microbiome trans-
forms indigestible substrates from food, such as xy-
loglucans, into short chain fatty acids, which can be 
used as energy source for the colonocytes [5]. These 
metabolic activities may directly or indirectly impact 
health and disease in the host. The commensal microbi-
ota can train the immune system to induce regulatory T 
cells, which then prompt tolerance to these bacteria [6]. 
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In this way, commensal-induced immunity contributes 
to maintain mucosal tolerance and protect the host from 
disease [7]. Such exchanges are tightly regulated: gut 
and immune cells continuously interact to distinguish 
between commensal microbiota, harmless foodstuff, and 
pathogens. A fine balance between inflammatory and 
anti-inflammatory status is needed to preserve intestinal 
homeostasis [8]. 
Interest in developing colon-targeted drug delivery 
systems has increased in recent years [9]. These 
formulations are intended for gastrointestinal-related 
diseases, such as colorectal cancer (CRC) and inflam-
matory bowel disease (IBD). Despite the numerous re-
search in this field, there are still questions that need to 
be answered, as differences in microbiome composition 
may ultimately impact drug metabolism between sub-
jects [10]. For example, which characteristics of the 
microbiome contribute to the pharmacokinetic differ-
ences between individuals? Does the region in the colon 
reflect a specific colonization pattern, which will later 
trigger metabolic differences? Do long-term alterations 
in the gut microbiome generate metabolic dysbiosis? If 
so, to what extent? Gaining insight into the gut meta-
bolic potency is essential, because characterization of 
the players involved in drug disposition in the gut will 
contribute to ensure optimal drug efficacy and safety 
profile. 
Existing colon-specific drug delivery systems hold 
some limitations. Besides the microbial influence on 
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drug bioavailability and pharmacokinetics, low solubil-
ity in presence of bile acids and the small aqueous vol-
ume in the colon may hinder drug efficacy [11]. Moreo-
ver, understanding drug transporter activity is funda-
mental to improve drug passive permeability. Current 
models to predict drug efficacy consider plasma con-
centrations to describe the pharmacokinetics and phar-
macodynamics. However, drugs designed for targeting 
the gut undergo an extensive first pass metabolic clear-
ance. This implies that the relation between plasma con-
centrations and efficacy has a low predictive value. For 
this reason, investigating microbiome-drug-host inter-
actions towards improving ADME and safety responses 
of intestinal targets is fundamental [12]. 
Xenobiotic Metabolism of the Gut 
Microbiome 
Chemotherapeutic outcomes are mainly linked to human 
genetic polymorphisms [13], but the impact of the hu-
man gut microbiome has been overlooked, as it has been 
even called the “forgotten organ”. Although microbi-
ome research has flourished in recent years, the associ-
ation between the microbiota and xenobiotics metabo-
lism remains underexplored. The host cytochrome 
CYP2C9 predominantly eliminates lipophilic drugs 
through the liver, whereas orally administered drugs 
encounter the gut microbiota before reaching host tis-
sues [10]. This first-pass metabolism by the colonic 
microbiota must be considered, as the metabolites gen-
erated from this process can impact drug activity, re-
sulting in toxicity for the host and further inflammation, 
or altering gut microbiota and producing dysbiosis [14]. 
The anaerobic environment of the human gut pre-
vents the microbial use of oxygen as terminal electron 
acceptor for oxidation [10, 14]. Thus, anaerobic respira-
tion and increase in microbial growth are facilitated by 
the two main metabolic transformations: reduction pro-
vides alternative electron acceptors, while hydrolysis 
ensures substrates that can be used by microorganisms 
[15]. Since these two reaction types are commonly ob-
served, core microbial species or core gene families 
performing such functions are hypothesized to partici-
pate [16]. 
Links between gut bacteria and drug metabolism are 
via direct and indirect mechanisms. Direct mechanisms 
involve the transformation of the drug into metabolites 
with a different effect. Conversely, indirect mechanisms 
are those influencing drug transport or metabolism [14]. 
Knowledge of these metabolic pathways is fundamental 
to predict whether drug metabolism and disposal will be 
impacted.  
Additionally, biliary excretion is essential for drug 
recirculation and ultimate metabolism. In this respect, β-
glucuronidases can play a key role, because they are 
important for host drug detoxification [17]. Glucuronic 
acid is coupled to several substrates in the liver, thereby 
increasing molecular weight and solubility. Conse-
quently, elimination through urine or faeces is en-
hanced, and gut bacteria can reactivate these products, 
generating higher toxicity. Likewise, non-steroidal anti-
inflammatory drugs (NSAIDs) have side-effects [18]. 
Microbial β-glucuronidases can separate the aglycone 
from the glucuronide, so the aglycone is absorbed into 
the enterocytes and transformed into reactive metabo-
lites, harming the mitochondria and the endoplasmic 
reticulum. In this way, not only the host detoxification 
pathway is diminished, but also inflammation is evoked 
as a result of decreased mucosal integrity [19]. The im-
pact of the gut microbiota on hepatic drug-processing 
genes is enzyme-specific and age and sex-dependent, 
with patterns varying throughout life span and devel-
opmental periods, and xenobiotic pathways significantly 
downregulated in male mice at 90 days of age [20]. 
Moreover, probiotic interventions have confirmed 
that microbiome manipulations not involving antibiotics 
can influence the expression of hepatic drug–processing 
genes during adulthood [21]. Poorly absorbed antibiot-
ics such as vancomycin and rifaximin, may indirectly 
modulate hepatic CYP gene expression, as they bypass 
hepatic metabolism and impact gut bacteria [22]. Under-
standing the outcomes of indirect host–microbiome-
drug interactions occurring because of drug use, con-
sumption of dietary supplements, or environmental 
toxins should be considered in drug development, safety 
pharmacology, and pharmacokinetic profiling [20]. 
The Gut Microbiome and Xenobiotic 
Metabolism during Chronic Inflammation 
Although research efforts are ongoing to more precisely 
define a healthy gut microbiome [23], one of the most 
frequently reported findings across an array of disorders 
is a narrowing of gut microbiome diversity often ac-
companied by more specific but less consistent compo-
sitional alterations at various taxonomic levels. Dysbio-
sis refers to the state where the composition of the mi-
crobiome is disrupted [24, 25], providing continuous 
immunological stimulation and leading to anomalies in 
the immune response. The polarized induction of im-
mune cells and the subsequent increased amounts of 
pro-inflammatory T cells may fuel the development and 
severity of the disease. Excessive inflammation results 
in loss of epithelial integrity, which in turn leads to fur-
ther bacterial translocation and thus further induction of 
inflammation [8, 24]. This condition is observed in a 
number of gastrointestinal diseases such as inflamma-
tory bowel disease (IBD) and colorectal cancer (CRC) 
[26], central nervous system disorders such as depres-
sion and schizophrenia [27], obesity [28], diabetes 
mellitus [29], cardiovascular disorders [30], rheumatoid 
arthritis [31] and multiple sclerosis [24], and asthma and 
atopy in children [32]. Research found that Faecalibacte-
rium prausnitzii is reduced in patients with ulcerative 
colitis, another chronic inflammatory condition of the 
colon [33]. This bacterium has been reported to promote 
the accumulation of regulatory T cells (Treg), which 
contribute to anti-inflammatory responses [34]. On the 
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contrary, Enterobacteriaceae, Bacteroides, Clostridium 
ramosum and Akkermansia muciniphila are increasingly 
present in patients with IBD. These organisms have also 
been linked with increased inflammation [35]. Although 
the importance of the gut microbiome in chronic 
inflammatory conditions has been reported [36], it is 
still unclear whether dysbiosis is a consequence or a 
cause of associated diseases [8, 24].  
Gut microbiota are known to play a role in the me-
tabolism of drugs, hereby having an effect on the host 
health . Many of the therapeutic interventions for 
chronic disorders are subject to biotransformation by the 
gut microbiome, and the functional implications of 
changes in gut bacterial communities for xenobiotic 
metabolism are yet to be described. The gut microbiome 
can affect drug therapy via direct or indirect mecha-
nisms. The direct mechanisms compromise metaboliza-
tion of the drugs by the microbiota, resulting in altered 
bioavailability of these compounds. Indirect mecha-
nisms include complex host-microbiome interactions, 
resulting in a modified xenobiotic metabolism of the host 
[10]. In the latter case, one of the routes is that microbiota 
affect host gene expression involved in drug metabolism. 
These effects can be either local, meaning in the gut 
tissue [37], or distant, including in the liver [38]. 
Understanding how alterations in gut microbiota 
profiles influence host response to chemotherapeutic 
drugs may have important clinical implications. Strati-
fying patients based on their gut microbiome composi-
tion may assist in identifying responders and non-re-
sponders to immunotherapy [39] for the treatment of 
epithelial tumours and melanomas [20, 40]. Other 
mechanisms modulated by the gut microbiome include 
the translocation and immunomodulation following 
interventions with cyclophosphamide, doxorubicin, and 
anti–CLTA-4 therapies [41].  
Dynamics of Nonsteroidal Anti-Inflammatory 
Drugs (NSAIDs) towards the Gut 
Microbiome 
Nonsteroidal anti-inflammatory drugs (NSAIDs) are a 
class of drugs used for inflammation management. The 
compounds in this group are heterologous in structure 
but show similar therapeutic activity [42]. The target of 
all NSAIDs are cyclooxygenase enzymes (COX). There 
are two isoforms of COX, the primarily constitutive 
form COX-1, and the inducible from COX-2 [42]. 
COX-1 and COX-2 both catalyse the conversion of ara-
chidonic acid to PGH2 [43]. PGH2 is the immediate 
substrate for some cell specific prostaglandin and 
thromboxane synthases [42].  
COX-1 is expressed in different tissues such as the 
kidneys, lungs, stomach, ileum and colon [44]. It is con-
sidered to be a “housekeeping” enzyme, playing an im-
portant role in the production of prostaglandins that 
serve homeostatic functions [45]. These prostaglandins, 
among others, maintain the integrity of the gastric mu-
cosa, mediate normal platelet function and regulate re-
nal blood flow [46]. COX-2 on the other hand, is nor-
mally not expressed in tissues with the exception of the 
macula densa of the brain and kidney, the placenta, the 
vessel walls and the heart, where it is believed to play a 
role in homeostatic functions [47]. This isoform of the 
enzyme is upregulated in response to tissue damage or 
the presence of pro-inflammatory cytokines [43]. In 
turn, COX-2 is responsible for the generation of pro-
inflammatory prostaglandins, thus contributing to in-
flammation [45]. One of these prostaglandins is PGE2, 
which is implicated in carcinogenesis. COX-2 expres-
sion is found to be increased in colorectal cancer caus-
ing proliferation, enhanced angiogenesis and suppres-
sion [48] of apoptosis (Pugh & Thomas, 1994; Surh et 
al., 2001).Thus, COX-2 is the main target of chronic 
inflammation therapy using non-steroidal anti-inflam-
matory drugs (Fig. 1). 
 
Fig. 1 Isoforms of COX enzymes and their functions 
Orally administered drugs are subject to the so 
called “first-pass metabolism”, where the gut microbi-
ome plays a crucial part. Prior to reaching the target 
tissue, microbiota and liver metabolize the drugs, alter-
ing their bioactivity [10]. The bacterial metabolism re-
sults in three scenarios, namely activation, inactivation, 
and increased toxicity of the drug. In the first situation, 
the pharmaceutical compound is activated into its thera-
peutic window, resulting in increased drug efficacy. An 
example is the described transformation of sulindac to 
its bioactive sulphide metabolite. In the case of inacti-
vation, the availability of the active drug is lowered 
resulting in decrease or loss of therapeutic effect. For 
instance, microbial arylamine N-acetyltransferases in-
activate the bioactive component of the anti-inflamma-
tory drug sulfasalazine [14], while the NSAID diclo-
fenac can exert toxic effects after being glucuronidated 
in the liver by the host and then being exposed to mi-
crobial β-glucoronidases in the gut [10, 18]. In these 
scenarios, activity of the gut microbiome results in in-
creased toxicity and adverse effects for the host. In ad-
dition, simultaneous use of probiotics significantly in-
creased the microbiota‐mediated enzymatic degradation 
of the antipyretic and analgesic paracetamol  [20, 39]. 
Similarly, short-term administration of a probiotic cocktail 
of L. acidophilus, B. lactis and Streptococcus salivarius 
to rats significantly increased azoreductase activity in ex 
vivo incubation of sulfasalazine with colon contents, 
ultimately impacting the metabolism of this drug [49]. 
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Besides the gut microbiome influencing drug metab-
olism, drugs also impact the microbial communities in 
the gut. As discussed earlier, a shift in gut microbiome, 
and more specifically dysbiosis, is linked to disease. 
Therefore, understanding the effects of drugs on the gut 
microbiota is crucial for providing suitable therapies [14]. 
Obvious examples include the use of antibiotics, resulting 
in altered gut microbiome [50]. NSAIDs have been re-
ported to impact the gut microbiome and changes in 
composition have been observed [51] depending on the 
NSAID administered. Subjects exposed to aspirin showed 
greater abundance in Prevotella spp., Bacteroides spp., 
Barnesiella sp. and Ruminococcaceae. Celecoxib and 
ibuprofen users showed enrichment in Enterobacteriaceae 
and Acidaminococcaceae. Ibuprofen users were also en-
riched in Propionibacteriaceae, Pseudomonadaceae, 
Puniceicoccaceae and Rikenellaceae [52]. In contrast, a 
different study observed no effects on the microbiome 
composition after administration of celecoxib [53]. Sul-
fasalazine induced the expression of thioredoxins and 
nitrate reductases, while nizatidine, subject to bacterially 
mediated N‐oxide bond cleavage, up‐regulated the 
expression of drug enzymes and transporters acting on 
nitrogen bonds  [54]. This finding supports the earlier 
hypothesis that drugs may shift the microbiota to favour 
the abundance of taxa involved in its metabolism. Fur-
thermore, this altered metabolic capacity of the micro-
biota could consequently affect not only the pharmaco-
kinetics of subsequent doses of the drug itself (a phenom-
enon referred to as autoinduction) but also the pharmaco-
kinetics of co‐administered medication may be act as 
substrates of the same metabolic pathway or transporter. 
Production of diet-derived by-products such as like p-
cresol (from protein digestion) can affect drug metabo-
lism. Research showed that acetaminophen, an analgesic 
and antipyretic drug, underwent less sulfonation due to 
competitive O-sulfonation of p-cresol [55]. 
COX-1 plays a role in guaranteeing the mucosal in-
tegrity of the gastrointestinal tract and thus, non-specific 
NSAIDs blocking  both isoforms of COX have been 
linked with intestinal damage [19]. These environmental 
changes place a selective pressure on the microbiome 
resulting in fluctuations in microbial composition [56]. 
Blocking intestinal bacterial enzymatic functions has 
been proposed to amend intestinal homeostasis, while 
enhancing efficacy and decreasing toxicity of IBD ther-
apies, as realised for cancer therapies [4, 17]. Precision 
editing of the gut microbiota by tungstate ameliorates 
experimental gut inflammation through preventing the 
dysbiotic expansion of Enterobacteriaceae [57]. This is 
merely an example of the complex host-microbiome-
drug interactions and it is likely that different drugs ex-
ert selective pressures on the gut microbiome through 
different mechanisms [14]. The use of designer lactic 
acid bacteria as factories for the production of antimi-
crobial and anti-inflammatory biomolecules may also 
have potential for the future treatment of infectious dis-
eases, cancer, and metabolic diseases [54, 58]. 
Conclusion 
It is clear that the gut microbiome play an enormous 
role in patient health, but also in pharmacokinetic and 
pharmacodynamic drug response. Before official ap-
proval, government agencies such as the FDA run three 
phases of clinical trials, where pharmacokinetics, phar-
macodynamics, and safety of a drug are determined. 
However, gut bacteria is not currently considered within 
these evaluations, although the microbiome is the first 
checkpoint following drug intake. In vitro studies have 
shown that some NSAIDs can be metabolized by bacte-
ria, potentially jeopardizing its anti-inflammatory ef-
fects. More than 60 interactions between drugs and the 
microbiome have already been documented. Unfortu-
nately, most of the underlying molecular and genetic 
mechanisms remain unclear. The PharmacoMicrobi-
omics online database was launched in 2011 to assem-
ble the literature about those interactions [59]. Future 
efforts may focus on combining available information 
about the drug-bug interactions on biochemical path-
ways with existing genomic, pharmacogenomic and 
human microbiome sequence databases [52].  
Personalized medicine has achieved  excellent re-
sults in some areas of medicine, such as oncology [4]. 
Yet, genetic factors can influence up to 50% of therapy 
responses [13]. It is at this crossroads that recent discov-
eries on the roles of gut microbiota have become para-
mount [60]. Stratification of patients based on their gut 
microbiome may improve treatment accuracy [17] and 
cost-effectiveness [61]. A combined strategy to restore 
eubiosis may require synchronised targeting of domi-
nant pathobionts and replacing missing beneficial spe-
cies or their functions by manipulating the bacterial 
microbiota with dietary strategies. Thus, homeostatic 
immune responses, and mucosal barrier function would 
be reconditioned. This integrated approach may result 
safer than the current lifelong treatments with immuno-
suppressive drugs, once remission has been accom-
plished by traditional therapies. 
Understanding how our "second genome" [4] is in-
volved in therapeutic responses could pave the way for 
approaches using the intestinal microbiome as the target 
for modulating drug efficacy and enabling tailored 
treatments. Revealing the specific mechanisms driving 
defective bacteria–host interactions will enable preci-
sion editing of gut microbiota functionality and compo-
sition for ameliorating chronic inflammatory diseases.  
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